Search results for "From ACP Journal Club"
In adults with HF with preserved ejection fraction and obesity, tirzepatide reduced a composite of CV death or worsening HF at 2 y
A manufacturer trial added to the evidence that incretin-based therapies improve cardiovascular (CV) outcomes in patients with obesity and heart failure (HF) with preserved ejection fraction, regardless of the presence of diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2025/04/11/7.htm
11 Apr 2025
Weekly efsitora compared to degludec in type 1 and type 2 diabetes by industry studies
Although two manufacturer trials showed that the weekly insulin efsitora was noninferior to daily degludec, that finding might not be sufficient to justify its use, particularly in patients with type 1 diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2025/01/10/6.htm
10 Jan 2025
After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y
Given that this large study found an elevated incidence of type 2 diabetes up to two years after infection, COVID-19 could now be characterized as a possible risk factor for diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/12/13/9.htm
13 Dec 2024
In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use
The number of patients who received combination therapy with an SGLT-2 inhibitor and a GLP-1 receptor agonist in a recent review was too small to guide practice, but it's likely that more patients will soon be on this regimen, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/7.htm
8 Nov 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT-2 inhibitors reduce HF hospitalizations and CV mortality
Recent research on newer classes of diabetes drugs indicates that dysglycemia may not be a prerequisite to benefit from their cardiovascular and renal benefits, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/6.htm
8 Nov 2024
In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81)
The new Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) score could potentially identify patients in primary care who are at risk for progressive fibrosis and facilitate interventions and treatment, but it needs to be prospectively validated, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/10/11/6.htm
11 Oct 2024
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y
A recent industry-funded trial solidifies glucagon-like peptide-1 receptor agonists as a treatment for patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD), but questions about safety in patients with advanced CKD remain, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/09/13/8.htm
13 Sep 2024
In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality
The most important implication of this new model for predicting cardiovascular disease (CVD) risk among patients with type 1 diabetes (T1DM) may be that it will motivate clinicians to initiate statin therapy in younger patients, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/07/12/6.htm
12 Jul 2024
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary
A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/05/10/8.htm
10 May 2024
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2024/05/10/7.htm
10 May 2024
In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y
An ACP Journal Club commentary noted that it's unknown whether lower-risk and younger statin-intolerant patients would derive the degree of benefit from bempedoic acid found in this study, since the industry-funded trial enrolled only high-risk and older patients.
https://diabetes.acponline.org/archives/2024/04/12/8.htm
12 Apr 2024
In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin
A new study provides some reassurance to patients who unintentionally become pregnant while taking diabetes drugs but should be interpreted with caution because the number of infants exposed was low and only pregnancies resulting in live births were included, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/04/12/7.htm
12 Apr 2024
In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA1c level at 6 mo
The small trial comparing time-restricted eating and calorie restriction with control was adequately powered to inform clinical practice, but larger trials with longer follow-up should be done to confirm the results, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/02/09/6.htm
9 Feb 2024
In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk
An ACP Journal Club commentary cautioned that although a recent industry-funded trial was designed to approximate real-world practice, certain factors may still limit the generalizability of its findings.
https://diabetes.acponline.org/archives/2024/01/12/7.htm
12 Jan 2024
In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 y
If confirmed, the findings of different disease trajectories among patients with latent autoimmune diabetes in adults could eventually merit reclassification of the types of diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/01/12/6.htm
12 Jan 2024
In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk
The new drugs known as “twincretins” represent a major breakthrough for patients with overweight or obesity, prediabetes, or diabetes, but obstacles will include supply, lack of cost-effectiveness evidence, and insurance coverage, an ACP Journal club commentary said.
https://diabetes.acponline.org/archives/2023/11/10/7.htm
10 Nov 2023
In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes
The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on gout in patients with type 2 diabetes or heart failure (HF) may allow reduced polypharmacy when treatment for gout is also needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/11/10/6.htm
10 Nov 2023
In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA1c vs. daily degludec at 26 wk
Weekly insulin icodec has shown potential benefit in recent trials, but data on its effects in patients with type 1 diabetes or renal or hepatic failure are still awaited, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2023/10/13/7.htm
13 Oct 2023
In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA1c at 26 wk
Weekly insulin injections might be optimal for patients with type 2 diabetes who are already taking weekly glucagon-like peptide 1 receptor agonists and need additional basal insulin, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/08/11/6.htm
11 Aug 2023
In types 1 and 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA1c at 26 wk
The arrival of once-weekly insulin will undoubtedly be welcomed by patients and clinicians, but the advantages of fewer shots will have to be weighed against less flexibility in dosing of basal insulin, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/07/14/7.htm
14 Jul 2023